Research 1st Roundup: July 2026
This quarter’s summaries highlight several studies examining the biological mechanisms of ME/CFS and Long Covid, including the roles of specific autoantibodies and persisting viral components in driving distinct symptoms. Several […]
Webinar Replay: GLP-1 Drugs to Reduce Symptoms in People with ME/CFS and Identify Disease Subgroups
Glucagon-Like Peptide-1 (GLP-1) agonist medications, like semaglutide, are injectable or oral drugs that mimic the natural GLP-1 hormone, which helps regulate insulin levels. Thus, these medicines help control blood sugar […]
GLP-1 Drugs to Reduce Symptoms in People with ME/CFS and Identify Disease Subgroups
Glucagon-Like Peptide-1 (GLP-1) agonist medications, like semaglutide, are injectable or oral drugs that mimic the natural GLP-1 hormone, which helps regulate insulin levels. Thus, these medicines help control blood sugar […]
New Catalyst Awards to Accelerate ME/CFS and Long Covid Breakthroughs
Solve M.E. is proud to support two pioneering studies through our latest round of ME/CFS Catalyst Awards, a focused initiative to support promising research projects that have already made significant […]
Autoantibody Treatments for ME/CFS and Long Covid: Dr. Scheibenbogen Urges Smarter, Targeted Research
Dr. Carmen Scheibenbogen is the director of the Institute for Medical Immunology at Charité Hospital (Berlin, Germany) and a world-leading expert on Long Covid and ME/CFS. She is also a […]